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Introduction
Cryopyrin-associated periodic syndrome (CAPS) is a
constellation of diseases with a different and varying
clinical spectrum which is rarely seen in childhood.
The mildest form of CAPS which is familial auto-
inflammatory syndrome and the most severe form
which is chronic inflammatory neurologic cutaneous
arthropathy (CINCA) possess a very different spectrum
of clinical findings. Most important organ involvement
in CAPS is the associated uveitis. Uveitis in CAPS
is unresponsive to most of the classic treatment
modalities.
Objectives
In this case report, we will describe the response of a
patient to canakunimab therapy whose uveitis associated




The female patient who was healthy until 3 years of age
developed urticarial rash associated with a 4 to 5 day
duration of fever which started to occur periodically
every 1 month. At 5 years of age, in addition to her per-
iodic complaints of fever and rash, arthritis occurred in
her left knee. After her admittance to our Rheumatology
Department with these complaints, chronic arthritis of
the right ankle was also detected. Her laboratory analy-
sis revealed a normal complete blood count while acute
phase reactant levels were elevated. ANA and RF were
found to be negative in the patient. Ophthalmologic
evaluation revealed episcleritis and chronic iridocyclitis.
The patient was given methotrexate, prednisone and
infliximab with varying doses and with varying dura-
tions. Despite different treatment modalities, her uveitis
and urticarial findings persisted. NLRP3/CIAS1 muta-
tion was investigated with the suspicion of CAPS.
T436A mutation was detected. Neurosensorial hearing
loss was not present in the patient. With the confirma-
tion of diagnosis of CAPS, patient was given canakuni-
mab therapy at a dose of 4 mg/every 2 months. After
the first dose, joint and skin findings of the patient
resolved completely. Her uveitis which was unresponsive
to all of the treatment modalities also resolved after the
first dose. Leukocytes in the vitreus also disappeared.
The patient is now at the 18th month of canakunimab
therapy and is totally asymptomatic without any flare of
her uveitis.
Conclusion
CAPS should be considered in the differential diagnosis
in children presenting with an urticarial rash and oli-
goarthritis. If there is uveitis associated with CAPS, one
of the most efficacious and safe drug for treatment is
the anti-interleukin 1b agent, canakunimab.
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